115 related articles for article (PubMed ID: 9403335)
1. Reduction of disease causative T-cells in experimental autoimmune disease models by a new antirheumatic drug, TAK-603.
Ohta Y; Fukuda S; Makino H
Immunopharmacology; 1997 Oct; 37(2-3):167-74. PubMed ID: 9403335
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulating and articular protecting activities of a new anti-rheumatic drug, TAK-603.
Ohta Y; Fukuda S; Baba A; Nagai H; Tsukuda R; Sohda T; Makino H
Immunopharmacology; 1996 Aug; 34(1):17-26. PubMed ID: 8880222
[TBL] [Abstract][Full Text] [Related]
3. Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quino line-3-carboxylate (TAK-603).
Baba A; Makino H; Ohta Y; Sohda T
Chem Pharm Bull (Tokyo); 1998 Jul; 46(7):1130-4. PubMed ID: 9692219
[TBL] [Abstract][Full Text] [Related]
4. TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis.
Ohta Y; Yamane M; Sohda T; Makino H
Immunology; 1997 Sep; 92(1):75-83. PubMed ID: 9370927
[TBL] [Abstract][Full Text] [Related]
5. Studies on disease-modifying antirheumatic drugs. III. Bone resorption inhibitory effects of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl) quinoline-3-carboxylate (TAK-603) and related compounds.
Baba A; Oda T; Taketomi S; Notoya K; Nishimura A; Makino H; Sohda T
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):369-74. PubMed ID: 10212387
[TBL] [Abstract][Full Text] [Related]
6. Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b:5,4-c']dipyridine derivatives and their anti-inflammatory effect.
Baba A; Mori A; Yasuma T; Unno S; Makino H; Sohda T
Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):993-9. PubMed ID: 10434400
[TBL] [Abstract][Full Text] [Related]
7. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis.
Aikawa Y; Tanuma N; Shin T; Makino S; Tanaka K; Matsumoto Y
J Neuroimmunol; 1998 Aug; 89(1-2):35-42. PubMed ID: 9726823
[TBL] [Abstract][Full Text] [Related]
8. Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
Baba A; Kawamura N; Makino H; Ohta Y; Taketomi S; Sohda T
J Med Chem; 1996 Dec; 39(26):5176-82. PubMed ID: 8978845
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulation of experimental autoimmune encephalomyelitis by staphylococcal enterotoxin D.
Matsumoto Y; Fujiwara M
Cell Immunol; 1993 Jul; 149(2):268-78. PubMed ID: 7687198
[TBL] [Abstract][Full Text] [Related]
10. The role of regulatory T cells in Lewis rats resistant to EAE.
Sun D; Wilson DB; Cao L; Whitaker JN
J Neuroimmunol; 1998 Jan; 81(1-2):177-83. PubMed ID: 9521620
[TBL] [Abstract][Full Text] [Related]
11. Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs.
Tagawa Y; Kiyota Y; Yoshimura Y; Motohashi M; Tanayama S
Arzneimittelforschung; 1998 Jul; 48(7):750-7. PubMed ID: 9706376
[TBL] [Abstract][Full Text] [Related]
12. Limiting-dilution analysis of the frequency of myelin basic protein-reactive T cells in Lewis, PVG/c and BN rats. Implication for susceptibility to autoimmune encephalomyelitis.
Matsumoto Y; Kawai K; Tomita Y; Fujiwara M
Immunology; 1990 Feb; 69(2):215-21. PubMed ID: 1689693
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells in experimental allergic encephalomyelitis. I. Frequency and specificity analysis in normal and immune rats of a T cell subset that inhibits disease.
Sun D; Whitaker JN; Wilson DB
Int Immunol; 1999 Mar; 11(3):307-15. PubMed ID: 10221642
[TBL] [Abstract][Full Text] [Related]
14. Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism.
Vandenbark AA; Celnik B; Vainiene M; Miller SD; Offner H
J Immunol; 1995 Dec; 155(12):5861-7. PubMed ID: 7499876
[TBL] [Abstract][Full Text] [Related]
15. Environmental modulation of autoimmune arthritis involves the spontaneous microbial induction of T cell responses to regulatory determinants within heat shock protein 65.
Moudgil KD; Kim E; Yun OJ; Chi HH; Brahn E; Sercarz EE
J Immunol; 2001 Mar; 166(6):4237-43. PubMed ID: 11238677
[TBL] [Abstract][Full Text] [Related]
16. T lymphocyte clones and experimental autoimmune diseases.
Cohen IR
Behring Inst Mitt; 1985 Aug; (77):88-92. PubMed ID: 2417586
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo immunopharmacological profile of Sch 40120.
Smith SR; Watnick AS; Kung T; Siegel MI
Immunopharmacol Immunotoxicol; 1993 Jan; 15(1):13-44. PubMed ID: 8450179
[TBL] [Abstract][Full Text] [Related]
18. TAK-603, new rheumatic drug, inhibits rat mixed lymphocyte reactions and prolonges rat skin allograft survival.
Fujita T; Ezoe K; Matsumoto Y; Saito T; Homma K; Jimbow K; Sato N
Transplant Proc; 2002 Jun; 34(4):1133-5. PubMed ID: 12072297
[No Abstract] [Full Text] [Related]
19. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations.
Schluesener HJ; Wekerle H
J Immunol; 1985 Nov; 135(5):3128-33. PubMed ID: 2413113
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autoimmune disease and the generation of suppressor cells by spirogermanium: a biological profile similar to total lymphoid irradiation.
Badger AM; Mirabelli CK; Swift BA; DiMartino MJ
Agents Actions; 1989 Jun; 27(3-4):335-7. PubMed ID: 2529742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
